Indivior PLC announced on July 23, 2025, results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports. The study found that patients treated with BUP-XR, the once-monthly long-acting injectable formulation of buprenorphine (SUBLOCADE), had 57% lower odds of all-cause emergency department (ED) visits compared to those who received no Medication for Opioid Use Disorder (MOUD).
The study also revealed that BUP-XR-treated patients experienced significantly fewer hospitalizations and lower inpatient costs compared to patients receiving daily oral buprenorphine or no MOUD. Inpatient costs for the BUP-XR group were nearly five times lower than for daily oral buprenorphine patients and more than 10 times lower than for patients receiving no MOUD.
Notably, no opioid overdose-related ED visits were recorded among patients in the BUP-XR cohort during the six-month follow-up period, compared to a 1.2% overdose rate in the daily oral buprenorphine cohort and 1% in the no MOUD cohort. These findings highlight the clinical and economic value of long-acting injectable treatments for OUD, potentially easing the burden on healthcare systems and supporting long-term recovery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.